APRIL与BAFF在IgA肾病中的作用
本文综述了APRIL和BAFF在IgA肾病发病机制中的作用。异常B细胞糖基化产生半乳糖缺陷型IgA1,与自身抗体形成免疫复合物。APRIL和BAFF是关键细胞因子,控制B细胞发育和抗体分泌细胞分化,靶向APRIL(联合或不联合BAFF)成为有前景的治疗策略,全球临床试验初步数据令人鼓舞。
要点
- APRIL和BAFF是控制B细胞发育和抗体分泌细胞分化的关键细胞因子。
- 靶向APRIL(联合或不联合BAFF)是IgA肾病有前景的治疗策略。
- 全球临床试验初步数据显示靶向APRIL/BAFF治疗结果非常积极。
核心结论
- 靶向APRIL联合或不联合BAFF是治疗IgA肾病有前景的策略,全球临床试验初步数据积极。
研究设计与样本
- 综述,总结遗传学、体外、体内及人类免疫学研究证据。
主要发现
- 循环中半乳糖缺陷型IgA1升高是IgA肾病发病的关键。
- 异常B细胞糖基化通路产生自身抗原,被自身抗体识别后形成免疫复合物。
- APRIL和BAFF是控制B细胞发育和抗体分泌细胞分化的关键细胞因子。
临床怎么用
- 靶向APRIL(联合或不联合BAFF)可作为IgA肾病的治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In IgA nephropathy (IgAN), elevated levels of the circulating autoantigen galactose-deficient IgA1 are critical to disease pathogenesis. Abnormal B-cell glycosylation pathways produce the autoantigen that, on recognition by autoantibodies, forms immune complexes. Genetic as well as in vitro, in vivo, and human immunologic studies have identified APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor) as key cytokines controlling B-cell development and the differentiation of antibody-secreting cells. Targeting APRIL with or without BAFF is emerging as a viable strategy for the treatment of IgAN and nascent data from global clinical trials are showing very promising results.
引用
- Reily C, Novak J, Rizk DV, et al. The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy. Am J Kidney Dis. 2026. PMID: 41794353. doi:10.1053/j.ajkd.2025.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。